© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
FDA approves Rozlytrek for cancers with certain gene mutations
The test was able to identify many cancers, and their location, at early stages.
First KRAS targeted therapy shows promise for lung and colon cancer
Even cancer that doesn’t affect the bones directly can contribute to bone problems.
The International Association for the Study of Lung Cancer made the declaration at the outset of a major cancer meeting in Barcelona.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
A related study finds patient and provider perceptions about barriers to trial participation are not in sync.
Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.
World Cancer Day is August 1, 2020.
The Supreme Court justice has now battled cancer four times.
New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
